GA-UNIBLOC-PUMP
8.9.2021 13:17:10 CEST | Business Wire | Press release
Unibloc Pump , a 37-year leader in the manufacture of positive displacement pumps, strainers, valves, bubble traps, and other solutions for sanitary flow control applications, today announced the acquisition of Flotronic Pumps , a UK-based manufacturer of specialized, air operated double diaphragm (AODD) pumps, and associated accessories. Founded in 1990, Flotronic Pumps has a global reputation as the inventor of the ‘One Nut’ AODD pump. Flotronic Pumps’ pioneering single bolt design significantly reduces process downtime by simplifying pump assembly / disassembly, providing savings in maintenance costs along with best-in-class air pump performance. Flotronic Pumps serves more than 1,000 global companies operating manufacturing facilities of iconic brands in food and beverage, consumer product goods, cosmetics, pharmaceuticals, and other critical process manufacturing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005041/en/
Terms of the agreement were not disclosed. Flotronic Pumps will be solely owned by US-based Unibloc Pump while retaining its name, Flotronic Pumps Ltd. Joining the leadership team at Flotronic Pumps as chief executive officer will be Chris Stevens, the CEO of Unibloc Pump. Stevens will provide commercial leadership with strengths in business-to-business marketing, channel management, sales, and overall business management.
“This acquisition is a perfect hand-in-glove fit for Unibloc Pump.” Stevens said. “Unibloc Pump and Flotronic Pumps are ready to drive accelerated growth by offering customers products and solutions fueled by our passions for innovation, safety, and simplicity in maintenance to avoid downtime and increase efficiencies,” Stevens added.
Through the leadership of owner Stuart Whitehouse and the deep expertise of Director of Sales Leighton Jones, Flotronic Pumps has witnessed significant growth in Europe, as well as North America. “What we really like most of all about joining the Unibloc Pump family is that we share many of the same cultural values of simplicity in product design, quality in products, unabashed customer-focus, deep industry expertise, and a penchant for strong innovation,” said Jones. “These qualities will ensure that Unibloc Pump and Flotronic Pumps will be successful moving forward by flourishing through common bonds,” added Jones.
“Important to this acquisition is that both companies share complementary market footprints,” commented Whitehouse. “The combination will enable Unibloc Pump to grow its UK and European business, while also giving Flotronic Pumps an unmatched North American foothold. That should pay off in greater market coverage and increased overall value delivered to the customer,” Whitehouse added.
Unibloc Pump seeks to expand its vision to build a global sanitary flow control platform that delivers operational excellence, while targeting highly regulated hygienic end market applications, such as food and beverage, meat and poultry, and pharmaceutical processing. Unibloc Pump’s investment in Flotronic Pumps will provide resources to allow both companies to continue to grow and strengthen their global businesses.
The acquisition will allow Flotronic Pumps to leverage Unibloc Pump’s operational, manufacturing, sales, and distribution capabilities in North America out of its Kennesaw, GA facility. Likewise, Unibloc Pump will utilize Flotronic Pumps’ operations, manufacturing, sales, and distribution footprint in the United Kingdom and other European markets to further complement Unibloc’s existing European operation, Unibloc-R&H GmbH , based in Beckum, Germany.
Unibloc Pump is a portfolio company of May River Capital, a Chicago-based private equity firm devoted to helping high-caliber, lower middle-market industrial businesses grow and thrive. May River Capital takes pride in its unique approach and track record of building businesses through long-term partnership and collaboration. Its leadership team has broad experience helping promising companies become successful mid-size industrial businesses.
ABOUT UNIBLOC PUMP
Since 1984, Unibloc Pump has provided manufacturers in the food and beverage, pharmaceutical, bakery and confection, meat and poultry, brewery, and transportation industries with precision-engineered sanitary pumps, strainers, valves, bubble traps, and other accessory products to tackle the toughest sanitary jobs. Unibloc Pump is the premier designer of efficient, easy-to-clean pumps that help customers fight downtime, achieve a lower cost of operation, and meet deadlines with confidence. For more information, please visit www.uniblocpump.com .
ABOUT FLOTRONIC PUMPS
Based in West Sussex, United Kingdom and founded in 1990, Flotronic Pumps is a manufacturer of specialized AODD pumps and associated accessories. Flotronic’s products take performance far beyond traditional style AODD pump technology with a distinctive single bolt design that allows for in-line assembly / disassembly to be accomplished quickly and efficiently, significantly reducing process downtime, while providing best-in-class performance. For more information, please visit www.flotronicpumps.com .
ABOUT MAY RIVER CAPITAL
May River Capital is a Chicago-based private equity firm focused on investing in lower middle-market, industrial growth companies. May River Capital invests in high-quality industrial growth businesses, including precision manufacturing, engineered products and instrumentation, specialized industrial services, and value-added industrial distribution services. For more information, please visit www.mayrivercapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom